期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 8, 期 1, 页码 1-8出版社
ELSEVIER SCIENCE INC
DOI: 10.1053/bbmt.2002.v8.pm11846351
关键词
Epstein-Barr virus; posttransplantation lymphoproliferative disease hematopoietic stem cell transplantation immunotherapy; cytotoxic T cells; anti-B-cell antibodies
资金
- NATIONAL CANCER INSTITUTE [R01CA074126] Funding Source: NIH RePORTER
- NCI NIH HHS [CA61386, CA74126] Funding Source: Medline
Uncontrolled expansion of donor-derived Epstein-Barr virus (EBV)-infected B cells has become a significant problem in recipients of allogeneic hematopoietic stem cell transplantations. Major risk factors for the early development of posttransplantation lymphoproliferative disease include the use of unrelated or HLA-mismatched related donors, selective T-cell depletion of donor marrow, and the use of antithymocyte globulin or monoclonal anti-T-cell antibodies for the prophylaxis and treatment of acute graft-versus-host disease. Over the past few years, the administration of in vitro-generated EBV-specific cytotoxic T cells or anti-B-cell monoclonal antibodies has provided effective options for the prophylaxis or treatment of posttransplantation lymphoproliferative disease. Advances in quantitative polymerase chain reaction-based assays allow both the precise measurement of EBV load in peripheral blood samples and the identification of high-risk patients for early initiation of therapy. A major remaining challenge is to assess the significance of an elevated EBV load posttransplantation and to determine the indications for preemptive treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据